We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

3 hedge funds and large institutions have $2.2M invested in Seelos Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

48% less capital invested

Capital invested by funds: $4.2M → $2.2M (-$2M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$140K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$140K
2
BIP
Brandes Investment Partners
California
-$38K
3
VKH
Virtu KCG Holdings
New York
-$22K
4
AIM
Acrospire Investment Management
Illinois
-$6K
5
IP
Intellectus Partners
California
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sarissa Capital Management
Connecticut
$1.64M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$316K -$140K -1 -33%
Franklin Resources
3
Franklin Resources
California
$75K +$140K +1 New
ARTA
4
A.R.T. Advisors
New York
$44K – – –
California Public Employees Retirement System
5
California Public Employees Retirement System
California
$29K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$28K – – –
TSS
7
Two Sigma Securities
New York
$18K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$17K – – –
Northern Trust
9
Northern Trust
Illinois
$15K – – –
UBS Group
10
UBS Group
Switzerland
$9K – – –
BlackRock
11
BlackRock
New York
$7K – – –
EWM
12
Evercore Wealth Management
New York
$3K – – –
AG
13
Advisor Group
Arizona
$1K – – –
Bank of America
14
Bank of America
North Carolina
$1K – – –
FANJ
15
Financial Architects (New Jersey)
New Jersey
$1K – – –
Group One Trading
16
Group One Trading
Illinois
$1K – – –
Morgan Stanley
17
Morgan Stanley
New York
$1K – – –
Wells Fargo
18
Wells Fargo
California
$1K – – –
FDCDDQ
19
Federation des caisses Desjardins du Quebec
Quebec, Canada
$791 – – –
AIM
20
Acrospire Investment Management
Illinois
– -$6K – –
BIP
21
Brandes Investment Partners
California
– -$38K – –
IP
22
Intellectus Partners
California
– -$3K – –
VKH
23
Virtu KCG Holdings
New York
– -$22K – –

SEEL Hedge Fund Activity: Q2 2017 in Review

3 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2017, worth a combined $2.2M — down 48% from $4.2M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new SEEL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $140K. The largest seller was Vanguard Group, cutting an estimated $140K.

  • 3 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2017, up from 2 in Q1 2017.
  • Funds reported $2.2M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2017, down 48% quarter-over-quarter.
  • 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2017 and 0 closed out, a net change of +1 holder.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2017 was Franklin Resources, an estimated $140K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2017 was Vanguard Group, an estimated $140K sold.

Based on aggregated 13F filings for Q2 2017.